Dendreon Starts Trial of Cancer Pill
Luke Timmerman4/21/09
Dendreon, the Seattle company developing an immune-stimulating therapy for prostate cancer, said today it has started a clinical trial of a cancer drug made in a more conventional pill form. The company will examine safety of D3263 at a variety of doses in patients with solid tumors. Dendreon has been advancing this program toward clinical trials to diversify its pipeline beyond Provenge, its lead drug candidate, which succeeded in a clinical trial earlier this month.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
